A Phase 1, Multi-center, Open-Label, Dose De-escalation Study to Evaluate the Safety and Efficacy of Talimogene Laherparepvec in Japanese Subjects With Unresectable Stage IIIB-IV Malignant Melanoma
Phase of Trial: Phase I
Latest Information Update: 30 Jun 2017
At a glance
- Drugs Talimogene laherparepvec (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Amgen
- 26 Jun 2017 Planned primary completion date changed from 22 May 2019 to 6 Jun 2019.
- 03 May 2017 Planned primary completion date changed from 6 Jun 2019 to 22 May 2019.
- 15 Mar 2017 Status changed from not yet recruiting to recruiting.